TABLE 1.

Demographic, sleep, clinical characteristics, and Psychological impact in the patients with narcolepsy type 1 and controls

Variable	Patients with NT1 (n = 52)	Controls (n = 50)
Demographic data
Male/female, n	14/36	21/31
Age, years, mean±(SD)	33.56 ± (11.59)	34.42 ± (15.11)
Education, years, mean±(SD)	13.50 ± (3.31)	14.42 ± (3.31)
Age at diagnosis, years, mean (SD)	17.06 ± (10.29)
Disease duration, years, mean (SD)	17.90 ± (10.62)
Medication used, n
Stimulants	14
Sodium oxybate	19
Antidepressant	9
Stimulants plus sodium oxybate	19
Sleepiness, sleep quality and clinical characteristics
ESS, mean (SD) Pre During P	_ 11.28 ± (4.53) 9.85 ± (4.50) 0.04*	_ 5.29 ± (2.79) 5.31 ± (3.04) 0.96
PSQI, mean (SD) Pre During P		_ 4.26 (2.25) 5.34 ± (2.88) 0.01*
SP‐H (NSS), mean (SD) Pre During p	_ 4.17 ± (4.32) 4.23 ± (4.54) 0.90
EDS‐NS (NSS), mean (SD) Pre During p	_ 13.25 ± (5.87) 10.79 ± (5.46) 0.00*
CATA (NSS), mean (SD) Pre During P	_ 5.38 ± (3.94) 5.10 ± (3.81) 0.55
NSS, mean (SD) Pre During P	_ 22.81 ± (11.12) 20.12 ± (10.26) 0.01*
Psychological impact IES‐R, mean (SD)
Total score	5.87 ± (1.91)	6.29 ± (1.99)
Intrusion	1.83 ± (0.66)	1.95 ± (0.74)
Avoidance	2.00 ± (0.67)	2.14 ± (0.68)
Hyperarousal	2.05 ± (0.82)	2.20 ± (0.78)

CATA, cataplexy; EDS‐NS, excessive daytime sleepiness and night‐time sleep; ESS, Epworth Sleepiness Scale; NSS, Narcolepsy Severity Scale total score; NT1, narcolepsy type 1; PSQI, Pittsburgh Sleep Quality Index; SP‐H, Sleep paralysis and hypnagogic hallucinations.

*p < 0.05